Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Exubera Reduced blood glucose levels in patients with Type 2 diabetes, from an A1c of 9.6 to 7.7%. An experimental inhaled insulin preparation called Exubera is effective in controlling blood sugar levels in type 2 diabetics over prolonged periods of time, the drug’s developers said on Tuesday.
The results, presented at the Annual Meeting of the European Association for the Study of Diabetes in Germany, showed that over 2 years Exubera reduced blood glucose levels in patients with type II diabetes, with a fall in HbA1c levels from 9.6% to 7.7%. HbA1c in patients in the control group, who took existing drugs without Exubera, fell to 8.1%.
The two-year trial was designed to assess the efficacy of Exubera when added to sulfonylurea or metformin. Some 304 patients completed the trial.
Pfizer Inc., which is developing the drug with Sanofi-Aventis and Nektar Therapeutics, said both groups showed a slight reduction in lung function but there was no significant difference between the two groups.
Concerns about reduced lung function have hampered progress of the product. Safety concerns caused the companies to conduct additional clinical trials, and delayed regulatory filing in the United States.
================================
Introducing the Sportbrain iStep
Technology for Tracking Health and Fitness
Simple to use- keep motivated, lose weight and stay fit
Chart your progress and monitor your fitness on our website
No monthly membership. For more…
https://www.istepx.com/
DID YOU KNOW:
Insulin Resistance is an independent specific marker of proliferative retinopathy that may characterize patients at increased risk for blindness who may benefit most from early screening and therapeutic intervention. PDR patients had higher IR and low-density lipoprotein cholesterol and triglyceride levels than background diabetic retinopathy (BDR) patients but comparable levels of glycosylated hemoglobin.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 9 4371-4376